Skip to contentP
Perspective Therapeutics, Inc.
P
CATXPerspective Therapeutics, Inc. Q2 2020 · 10-Q
Revenue$2.21M$2.21M+15.9% vs Q2 2019 Net Income-$897.00K-$897.00KN/M vs Q2 2019 EPS Diluted-$0.01-$0.01N/M vs Q2 2019 Gross Profit$1,111,000+45.2% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Perspective Therapeutics, Inc. · CIK 728387 · Engraved from SEC EDGAR
Operating Cash Flowderived-$1,278,000N/M Free Cash Flowderived-$1,384,000N/M Margins · derivedGross margin50.4%+10.2 pt vs Q2 2019
Operating margin-40.9%+34.1 pt vs Q2 2019
Net margin-40.7%+33.6 pt vs Q2 2019
ended Dec 31, 2019 · filed Feb 12, 2020 · 43 d after period end